Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy

NCT05206513 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

86

Enrollment

INDUSTRY

Sponsor class

Conditions

Dyskinesia
Cerebral Palsy

Interventions

DRUG: Placebo
DRUG: Valbenazine

Sponsor

Neurocrine Biosciences